Enochian Biosciences, Inc. (ENOB) News
Filter ENOB News Items
ENOB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ENOB News From Around the Web
Below are the latest news stories about Enochian Biosciences Inc that investors may wish to consider to help them evaluate ENOB as an investment opportunity.
Enochian BioSciences, Inc.: Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid TumorsLOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) - Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today |
Enochian BioSciences Announces Scientific Presentation at World Vaccine Conference on Promising Human and Laboratory Data to Potentially Treat Solid TumorsLOS ANGELES, Dec. 03, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Dr. Serhat Gumrukçu, Inventor and Co-Founder of Enochian BioSciences, and Founder and Director of Seraph Research Institute (SRI), presented new data and announced a partnership between Enochian and Dr. Anahid Jewett, a leader in tumor immunology and cell and gene therapy, on pancreatic cancer, as well as a combined effort with SRI and Enochian on Glioblastoma. |
Vanguard Group Inc. Sells 52,662 Shares of Enochian Biosciences, Inc. (NASDAQ:ENOB)Vanguard Group Inc. reduced its stake in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 16.1% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 273,656 shares of the companys stock after selling 52,662 shares during the period. Vanguard Group Inc.s holdings in Enochian Biosciences were worth [] |
Enochian Biosciences (NASDAQ:ENOB) Shares Up 6.6%Enochian Biosciences, Inc. (NASDAQ:ENOB)s share price shot up 6.6% on Wednesday . The stock traded as high as $10.00 and last traded at $10.00. 1,000 shares were traded during mid-day trading, a decline of 99% from the average session volume of 198,485 shares. The stock had previously closed at $9.38. The company has a debt-to-equity [] |
Bank of New York Mellon Corp Lowers Stock Position in Enochian Biosciences, Inc. (NASDAQ:ENOB)Bank of New York Mellon Corp lowered its position in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 78.1% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 11,377 shares of the companys stock after selling 40,638 shares during the period. Bank of New York Mellon Corps holdings in Enochian Biosciences were worth $57,000 as of its most [] |
Bank of New York Mellon Corp Has $57,000 Stock Holdings in Enochian Biosciences, Inc. (NASDAQ:ENOB)Bank of New York Mellon Corp reduced its holdings in Enochian Biosciences, Inc. (NASDAQ:ENOB) by 78.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 11,377 shares of the companys stock after selling 40,638 shares during the period. Bank of New York Mellon Corps holdings in Enochian Biosciences were worth $57,000 at the end of [] |
Enochian Biosciences Inc. (NASDAQ: ENOB) Gain Of 72.1% Compared To 52-Week Low; YTD Rise 215.93% What Should You Do Now?Enochian Biosciences Inc. (NASDAQ:ENOB)s traded shares stood at 0.32 million during the last session, with the companys beta value hitting 0.53. At the close of trading, the stocks price was $9.32, to imply an increase of 4.84% or $0.43 in intraday trading. The ENOB shares 52-week high remains $12.99, putting it -39.38% down since that Enochian Biosciences Inc. (NASDAQ: ENOB) Gain Of 72.1% Compared To 52-Week Low; YTD Rise 215.93% What Should You Do Now? Read More » |
Comparing Aeterna Zentaris (NASDAQ:AEZS) & Enochian Biosciences (NASDAQ:ENOB)Aeterna Zentaris (NASDAQ:AEZS) and Enochian Biosciences (NASDAQ:ENOB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Profitability This table compares Aeterna Zentaris and Enochian Biosciences net margins, return on equity and [] |
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 monthCompany encouraged by clear path to IND in near-term following its review of the FDAs Center for Biologics Evaluation and Research written comments Company encouraged by clear path to IND in near-term following its review of the FDAs Center for Biologics Evaluation and Research written comments |
Enochian BioSciences Announces the Successful Completion of an FDA Pre-IND for a Potential Cure for HIV: The Second Pre-IND in 1 monthCompany encouraged by clear path to IND in near-term following its review of the FDA’s Center for Biologics Evaluation and Research written commentsLOS ANGELES, Oct. 18, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) − Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced the completion of an Investigator Pre-Investigational New Drug (IND) process following receipt of written comments from the U.S. Food and Drug A |